Syed Ali

Syed Ali is an experienced executive in program management with a strong background in late-stage clinical development and oncology. At Acrivon Therapeutics, Inc., Syed held the title of Executive Director and Senior Director, overseeing various cross-functional teams and managing NDA and MAA preparations. Previously, at Albireo Pharma, Inc., Syed was responsible for leading global development teams for the pediatric rare disease treatment, Bylvay, and handling regulatory submissions. Syed's earlier roles include Director of Program Management for clinical development at ImmunoGen, Inc., and Director of Oncology Discovery Programs at ArQule, where significant milestones were achieved through strategic partnerships and management of discovery projects. Educational qualifications include project management certification from the University of Massachusetts Lowell and a postdoctoral fellowship in medicinal and pharmaceutical chemistry from the University of Kansas.